Neuraxis (NRXS) Income from Continuing Operations (2022 - 2025)
Neuraxis (NRXS) posted Income from Continuing Operations of 1683389.0 for Q4 2025, up 20.96% sequentially from 2129746.0 in Q3 2025, and down 26.71% YoY from 2297033.64 in Q4 2024.
Neuraxis (NRXS) Income from Continuing Operations (2022 - 2025) Analysis & Trends
Neuraxis has reported Income from Continuing Operations for 4 years, with the latest figure at 1683389.0 in Q4 2025.
- Quarterly Income from Continuing Operations fell 26.71% year-over-year to 1683389.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 8202908.0 (down 6.71% YoY) and the FY2025 annual result came in at 8191040.0, down 5.87% from the prior year.
- Income from Continuing Operations climbed to 1683389.0 in Q4 2025 per NRXS's latest filing, from 2129746.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 704032.0 in Q2 2022 and troughed at 3122864.0 in Q3 2023.
- A 4-year average of 1736198.73 and a median of 1683389.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations tumbled 139.51% in 2023, then jumped 45.05% in 2024.
- Over 4 years, Income from Continuing Operations stood at 1027716.0 in 2022, then plunged by 58.07% to 1624552.0 in 2023, then increased by 18.22% to 1328488.0 in 2024, then slipped by 26.71% to 1683389.0 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 1683389.0, 2129746.0, and 2092438.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.68 Mn |
| Sep 30, 2025 | -2.13 Mn |
| Jun 30, 2025 | -2.09 Mn |
| Mar 31, 2025 | -2.30 Mn |
| Dec 31, 2024 | -1.33 Mn |
| Sep 30, 2024 | -1.72 Mn |
| Jun 30, 2024 | -2.78 Mn |
| Mar 31, 2024 | -1.86 Mn |
| Dec 31, 2023 | -1.62 Mn |
| Sep 30, 2023 | -3.12 Mn |
| Jun 30, 2023 | -1.31 Mn |
| Mar 31, 2023 | -1.06 Mn |
| Dec 31, 2022 | -1.03 Mn |
| Sep 30, 2022 | -1.30 Mn |
| Jun 30, 2022 | -704,032.00 |